Aurinia's revenue has expanded from $57.2M in 2024Q2 to $83.7M in 2026Q3, and gross margin has held between 84.4% and 92.1% across recent quarters, suggesting a high-margin product mix with durable growth.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 30, 2026 | $0.23+4.5% vs $0.22 | $84M+0.1% vs $84M |
Q3 2026 Aug 6, 2026 | $0.28+16.7% vs $0.24 | $83M+3.4% vs $80M |
Q2 2026 May 7, 2026 | $0.25+38.9% vs $0.18 | $78M+0.9% vs $77M |
Q1 2026 Feb 26, 2026 | $0.26+23.8% vs $0.21 | $77M+3.2% vs $75M |
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.23 per share a year ago.
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025. Net Product Sales: For th.
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Benchmark AUPH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Aurinia Pharmaceuticals Inc. (AUPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.46 | $2.12B | 7.08 | 20.38% | 97.68% | 51.92% | — | |
| $306.20 | $6.14B | 118.77 | 60.4% | 20.27% | 5.22% | — | |
| $67.41 | $1.53B | 12.51 | 43.78% | 11.22% | 20% | 0.08% | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $72.77 | $7.81B | 55.34 | 12.79% | 16.81% | 22.94% | — | |
| $50.33 | $100.84B | 17.69 | 4.11% | 12.96% | 23.31% | 3.23% |
Aurinia Pharmaceuticals Inc. (AUPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Aurinia Pharmaceuticals Inc. (AUPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 30, 2026·SEC
Aug 6, 2026·SEC
Jun 4, 2026·SEC
Get notified when AUPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aurinia Pharmaceuticals Inc. (AUPH) stock FAQ — growth, dividends, profitability & financials explained
Aurinia Pharmaceuticals Inc. (AUPH) reported $321.7M in revenue over the trailing twelve months. Revenue was $283.1M in fiscal year 2025. That is 36131% more than the $0.8M of fiscal year 1998.
Aurinia Pharmaceuticals Inc. (AUPH) grew revenue by 21.0% over the trailing twelve months, compared with the twelve months before.
Yes. Aurinia Pharmaceuticals Inc. (AUPH) earned $314.3M in net income over the trailing twelve months (a 97.7% net margin).
Aurinia Pharmaceuticals Inc. (AUPH) had a return on equity (ROE) of 51.9% over the trailing twelve months. That is well above the market's typical 10-15%.
Aurinia Pharmaceuticals Inc. (AUPH) generated $175.5M in free cash flow over the trailing twelve months.
